TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Industry News Articles > Clinical trials in the post Brexit Europe

Clinical trials in the post Brexit Europe

While negotiations are still ongoing, the structure of the post-Brexit medicine testing and approval process is still unclear, and the UK government has so far ruled out an extension to the transition period which is due to come to an end at the end of this year. What is clear is that the Medicines and Healthcare products Regulatory Agency (MHRA) is becoming independent to the EMA’s drug approval and oversight process. It might result in the testing and release of products being completed under two separate regulatory frameworks.

Due to these uncertainties, the best way to be ready is not to wait for a potential agreement but prepare for the worst and assume a “no-deal” scenario. The focus of this article is implementing clinical trials in the post Brexit Europe.

The EU rules for clinical trials, which are set out in EU Directives including 2001/20/EC [1], may be no longer be applicable to the UK and this is concerning for the many European companies that run clinical trials and have study sites in the UK or rely on the UK for the supply of their investigational medicines. Because of Brexit, and in the absence of any special agreement for continued cooperation under a European medicines regulatory network, the UK would no longer participate in the free movement of goods within the EU – there is no clear pathway of how the trade of pharmaceutical products will work. The active substance and finished products coming from a UK-based manufacturing site may therefore be considered a third country importation of medicinal products into the EU. Similarly, for companies that have study sites in the UK, careful consideration must be given to how investigational medicines entering the UK from the EU must be handled after the end of the transition period. As such, there are some points to consider when conducting clinical trials:

  • The sponsor or legal representative must specify an authorized importer established in the EU.
  • The products must be released by a QP who is based within the European Economic Area (EEA) to ensure that the clinical trial product is manufactured in accordance with EU GMP and that the batches produced are verified in accordance with the EU Clinical Trial Authorization. With short shelf life products such as Advanced Therapy Medicinal Products (ATMPs), this brings an additional challenge to the release and distribution process.
    As the currently approved labeled product has to be modified in accordance to the change of manufacturing site or QP release site. This change has also to be notified with the relevant authorities.
  • When it concerns an authorized product, the pharmacovigilance system master file must be located in the EEA for all companies intending to conduct clinical trials in the EU.

The company must establish a legal representative in the EU and adapt their distribution channels to take importation requirements into account. To change the legal representative from a UK based to an EU based company, it requires a substantial amendment and notification to the Ethics Committee of the relevant competent authority. The Committee responds within a maximum of 60 days from the date of receipt of the notification. However, for certain investigational medical products (IMPs) such as gene therapies and somatic cell therapies, an additional extension of 30 days applies, which means a further 90 days in total for approval in some cases. As an example; if the notification is received on the 15th of August it can take up to the 14th of October before the approval is received. In case of a 90-day approval period the date would be the 13th of November, which is very close to the withdrawal date. For xenogenic cell therapies, there is no time limit to the authorization period. This could have a major impact on ongoing and planned clinical trials as some regulatory authorities have indicated that clinical trials may be suspended if submissions and approvals are not in place by the end of the transition period on the 31st of December 2020. Hence, preparation and timely submission becomes critical.

  • Results from clinical trials conducted in the UK completed before the 31st of December 2020 must be submitted to the European Central Database for Clinical Trials – EudraCT.
  • Sponsors with study sites in the UK should check that their supply chain and regulatory operations are similarly reviewed to ensure that their study remains compliant with regulatory requirements in the UK in the increasingly likely event of divergence.

In conclusion, as long as there is no longer term Brexit agreement in place, one must plan for the worst-case scenario which means preparing for a ”no deal” scenario whereby the EU and the UK fully diverge with respect to medicines regulation and the healthcare sector no longer benefits from concerted approaches under a European medicines regulatory network. As such, it is incumbent on all clinical trial sponsors to evaluate their current regulatory status and supply chains vis à vis Brexit impact, whether they have study sites in the EU and/or the UK.

Having regulatory subject matter experts and Qualified Persons available with in-depth experience of the requirements for conducting clinical trials throughout Europe, with expertise surrounding both EU and UK requirements, PharmaLex is highly equipped to support your organisation to deal with the upcoming impact. If you would like our team to examine your Brexit Strategy and work with you to prepare for the future, please connect with us to discuss – contact@pharmalex.com.

References

Directive 2001/20/EC of the European Parliament and of the Council [INTERNET] available from https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_20/dir_2001_20_en.pdf

Related posts
Why collaboration and an Integrated Product Development program are key to successful drug development
Why collaboration and an Integrated Product Development program are key to successful drug development
14th June 2022
Key Takeaways from the PDA Europe Annex 1 Workshop
Key Takeaways from the PDA Europe Annex 1 Workshop
7th June 2022
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Search
Upcoming Webinars

June 28th, 2022

eCTD in Australia: key steps to start a successful submission

08:30 am CET / 4:30 pm AEST

June 28th, 2022

An Introduction to Bayesian adaptive methods in clinical trials

04:00 PM CET

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
18h

Milena Shuytsova-Mircheva and Lisa Pascoe latest blog here https://www.pharmalex.com/sponsors-gear-up-for-a-smoother-process-with-ctis-but-must-first-overcome-key-hurdles/ discusses the benefit of the Clinical Trial Information System (CTIS).

💡 Interested in CTIS? Take the Phlexglobal survey to evaluate your preparation https://www.phlexglobal.com/ctis-survey

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • During the bid defense we felt that you worked well as team and are very dynamic. Preparation of such a complex dossier really needs to be done in such a way.

    Large Pharma, Germany
    VP Regulatory Affairs
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for